English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 854251      Online Users : 1377
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14962


    Title: Using precise boron neutron capture therapy as a salvage treatment for pediatric patients with recurrent brain tumors
    Authors: Chen, YW;Lan, TL;Lee, YY;Lin, KH;Liang, ML;Chen, HH;Pan, PS;Chang, FC;Wu, CC;Lin, SC;Kang, YM;Lee, JC;Liu, HM;Chen, KH;Chen, JK;Lin, CF;Kuo, YC;Hsu, SM;Huang, WS;Chou, FI
    Contributors: Institute of Biomedical Engineering and Nanomedicine
    Abstract: Background: Boron neutron capture therapy (BNCT) is a precise targeted particle therapy. Its principal purpose is to specifically administer boron-10-containing drugs to tumor cells and subsequently irradiate them with thermal neutrons. This highly explosive tumor destruction method exclusively attacks tumor cells that uptake boron-10-containing drugs, while minimizing damage to the surrounding normal cells without drug uptake, thereby making it an ideal option for the precise treatment of pediatric patients with recurrent brain tumors. Methods: Since March 2017, Taipei Veterans General Hospital collaborated with the Nuclear Science and Technology Development Center of National Tsing-Hua University to develop a salvage BNCT for recurrent tumors in the central nervous system. BNCT was delivered to patients using the research reactor of Tsing-Hua University. As of January 2020, a total of nine BNCT treatments (10 sites) have been performed on five pediatric patients with recurrent brain tumors. Results: The diagnoses of all five patients were recurrent glioblastomas, two of which developed from the brainstem. The median follow-up duration was 5.3 months. After BNCT, one site had complete response, and three had partial response. The median progression-free interval was 3.8 months. None of the five patients showed severe normal brain tissue necrosis nor serious complications after treatment. Conclusions: Pediatric patients are a vulnerable group with medical needs that are distinct from those of adult patients. BNCT is a precise cancer treatment for pediatric recurrent brain tumors with less normal toxicities and high tumor response.
    Date: 2020-12-30
    Relation: Therapeutic Radiology and Oncology. 2020 Dec 30;4:Article number 6521.
    Link to: http://dx.doi.org/10.21037/tro-20-20
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85129028197
    Appears in Collections:[陳仁焜] 期刊論文

    Files in This Item:

    File Description SizeFormat
    SCP85129028197.pdf643KbAdobe PDF92View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback